Karl Handelsman

Karl invests in series A synthetic biology and therapeutic startups.  Codon Capital is the "Unicorn Whisperer"  and also has four companies that exited in less than 18 months from their series A.

Tuesday
May 06
Personal Care 2030-2035
3:30 PM

-

4:15 PM

The convergence of AI, synthetic biology, and digital technologies is set to revolutionize consumer products. How will these exponential advances, coupled with biohacker innovations and the imperatives of sustainability and climate change, transform the personal care landscape by 2035? Discover how to harness these trends and actively shape the future of personal care. Leave inspired, informed, and ready to drive innovation in your organization.

Thursday
May 08
Risk, Resilience & Returns: New Frameworks for SynBio Investment
8:35 AM

-

9:00 AM

Bringing together leaders in synthetic biology and finance, this session scrutinizes new methods for balancing uncertainty, sustaining resilience, and optimizing returns in a field characterized by rapid innovation and protracted development timelines. Panelists will examine strategies for portfolio diversification across pivotal subfields—ranging from biomaterials to industrial fermentation—while highlighting the vital role of thorough scientific diligence and regulatory insight. By emphasizing the synergy between rigorous research and principled investment approaches, this discussion offers a timely examination of how careful planning can guide groundbreaking discoveries from the laboratory into sustained commercial success.

Other Speakers

Social Media

Other

Copyright SynBioBeta 2025

Social Media

Other

Copyright SynBioBeta 2025

Social Media

Other

Copyright SynBioBeta 2025